• 1
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:12451255.
  • 2
    Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008;29:12991305.
  • 3
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:12641273.
  • 4
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;127:3550.
  • 5
    Trevisani F, Santi V, Gramenzi A, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol. 2007;102:24482457.
    Direct Link:
  • 6
    Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119126.
  • 7
    Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291297.
  • 8
    Izzo F, Piccirillo M, Albino V, et al. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford). 2013;15:985990.
  • 9
    Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:10201022.
  • 10
    European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908943.
  • 11
    Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis. 2013;45:712723.
  • 12
    Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellular carcinoma serum markers. Semin Oncol. 2012;39:410433.
  • 13
    Sherman M. Current status of alpha-fetoprotein testing. Gastroenterol Hepatol. 2011;7:113114.
  • 14
    Sherman M, Bruix J, Porayko M, Tran T; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56:793796.
  • 15
    Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol. 1998;93:24522456.
  • 16
    Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524532.
    Direct Link:
  • 17
    Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434441.
  • 18
    Chen TM, Huang PT, Tsai MH, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669675.
  • 19
    Sterling RK, Wright EC, Morgan TR, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107:6474.
  • 20
    Sherman M. α-Fetoprotein: an obituary. J Hepatol. 2001;34:603605.
  • 21
    Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570575.
  • 22
    Giannini EG, Farinati F, Trevisani F. Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. Hepatology. 2011;54:376377.
  • 23
    Giannini EG, Erroi V, Trevisani F. Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? Expert Rev Gastroenterol Hepatol. 2012;6:441444.
  • 24
    El-Serag HB, Kanwal F. α-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013;11:441443.
  • 25
    Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time. Clin Gastroenterol Hepatol. 2013;11:437440.
  • 26
    Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986994.
  • 27
    Xu XS, Qu K, Liu C, et al. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol. 2012;18:72427250.
  • 28
    Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer. 1989;64:17001777.
  • 29
    Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutation. Int J Cancer. 2004;112:4450.
  • 30
    Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last 2 decades in Italy. J Hepatol. 2012;56:397405.
  • 31
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646649.
  • 32
    Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462503.
  • 33
    Paradis V. Histopathology of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:2132.
  • 34
    Watanabe A, Shiota T, Hayashi S, Nagashima H. Serum alphafetoprotein in fulminant hepatitis and hepatic regeneration following partial hepatectomy. Biochem Med. 1984;32:132137.
  • 35
    Horn KD, Wax P, Schneider SM, et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. Am J Clin Pathol. 1999;112:351357.
  • 36
    Asahina Y, Tsuchiya K, Nishimura T, et al. α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:12531262.
  • 37
    Oze T, Hiramatsu N, Yakushijin T, et al. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy [published online ahead of print December 7, 2013]. Clin Gastroenterol Hepatol. 2013.
  • 38
    Farinati F, Sergio A, Giacomin A, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 2009;21:12121218.
  • 39
    Giannini EG, Marabotto E, Savarino V, et al. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7:580585.
  • 40
    Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis. 2012;32:3038.
  • 41
    Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US [published online ahead of print December 25, 2013]. Hepatology. 2013.
  • 42
    Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814819.
  • 43
    Lee YK, Kim SU, Kim do Y, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization [serial online]. BMC Cancer. 2013;13:5.
  • 44
    Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101107.